Despite the improvements in surgical techniques, equipment, and staging of newly diagnosed patients with PCa that have been attained since the introduction of serum prostate-specific antigen (PSA) screening, 11–38% of patients after RP still have PSM [5, 6]. Here, KLK3 is linked to posterior cortical atrophy.